| INTRODUCTION
Autoantibody testing is performed to help diagnose patients with clinical symptoms indicative of possible autoimmune diseases. Antinuclear antibodies (ANA) are present in many systemic autoimmune conditions such as systemic lupus erythematosis (SLE). 1 However, a positive ANA test may also be seen with nonautoimmune inflammatory diseases, including infections.
Hepatitis C virus (HCV) infection is often associated with extra-
hepatic symptoms such as arthralgias, arthritis, vasculitis, and sicca syndrome that could signify a rheumatic disease. 2 Autoantibodies are commonly found in patients with HCV. Several investigators have studied whether patients with HCV and with a positive ANA result have a different disease profile, 3, 4 while others have concluded that the ANA positivity is an immunological epiphenomenon that has no influence on the response to therapy or histology. 5, 6 However, reports of ANA prevalence range vary widely from 3% to 41%. The most useful studies of hepatitis C and ANA positivity, however, are those that directly compare chronic hepatitis C patients to control groups using the same methodology. [7] [8] [9] In these studies, the ANA positivity rate in the HCV patient group varied from 12%-17.6% vs 3%-4% in the control group. All of these studies, however, used the standard method indirect immunofluorescence assay (IFA) as the methodology to screen for the detection of ANA. were undergoing hemodialysis. The prevalence of anti-ENA antibodies was significantly higher in patients with HCV infection undergoing hemodialysis, compared to hepatitis C-positive blood bank donors. 13 In this study, we aim to further analyze the profile of autoantibodies in hepatitis C-positive patients compared to a healthy control population using a new multiplex immunoassay that detects multiple autoantibodies simultaneously.
| MATERIALS AND METHODS

| Human sera
Between 
| Screening for hepatitis C virus infection by serology
Hepatitis C virus antibodies IgG and IgM were measured using the Abbott EIA, a chemiluminescent microparticle immunoassay (CMIA) performed on the Abbott ARCHITECT i2000 SR Immunassay System (Abbott Laboratories, Abbott Park, IL, USA). Specimens with signal to cut-off ratio (S/CO) values ≥1.00 are considered reactive by the ARCHITECT anti-HCV assay.
| HCV quantitation
Hepatitis C virus quantitation of RNA was performed on the Abbott m2000 Real Time System (Abbott Park, IL, USA) using real-time polymerase chain reaction (PCR).
| ANA testing
Antinuclear antibodies were performed according to the manufacturer's instructions with a 1:40 screening dilution using the Kallestad
HEp-2 Cell Line Substrate (Bio-Rad Laboratories, Hercules, CA, USA).
All specimens displaying greater than 1+ fluorescence at the 1:40 screening dilution were titered to endpoint. Both antinuclear and cytoplasmic observations of fluorescence were reported.
| ENA profile
The BioPlex 2200 (BioPlex) system (Bio-Rad Laboratories) was used 
| Statistical analysis
Comparisons of groups were performed using a Yates' corrected chi-
Additional statistical analyses were performed using an Excel spreadsheet (Microsoft Corp., Redmond, WA, USA) and SPSS software (SPSS Inc. Chicago, IL, USA).
| RESULTS
| Prevalence of anti-ENA antibodies in patients positive for HCV antibodies
Fourteen of the 100 HCV antibody-positive patients (14.0%) were also positive for anti-ENA antibodies (Table 1) The mean S/CO ratio HCV antibody value for all of the 100 HCV antibody-positive patients was 11.2 (±3.8 SD) ( Table 2 ). The mean S/ CO ratio for the HCV antibody-positive, anti-ENA-positive patients was 10.3 (±5.2 SD). 
| HCV RNA detection
| Anti-ENA patterns in patients positive for HCV antibodies
The most predominant anti-ENA pattern in the HCV-positive patients was anti-SSA or anti-dsDNA (Table 1 and Figure 1A) , with four patients each (28.6%) being positive for these antibodies. This was followed by anti-RNP and Scl-70, with three patients (21.4%) positive for these antibodies. Two of the healthy controls (one male and one female) were also positive for anti-RNP, while one healthy control (female) was positive for anti-Scl-70 ( Figure 1B) .
Ten of the 14 HCV antibody-positive patients were positive by IFA:
five had antinuclear patterns, one had combined antinuclear and cytoplasmic patterns, and four had a cytoplasmic pattern (Table 1 ). Titers ranged from 1:40 to 1:160, with various nuclear and cytoplasmic patterns present, including: speckled, homogenous, and centromere ANA patterns along with cytoplasmic fiber or speckled patterns. There were three speckled ANA patterns and two homogenous ANA patterns. The predominant cytoplasmic pattern was homogenous. One HCV antibodypositive patient was negative for anti-ENA, but positive by IFA for ANA with a speckled antinuclear pattern and a titer of 1:160 (Table 1 ).
All three HCV antibody-negative healthy control patients that were positive for anti-ENA antibodies were positive for ANA by IFA; a 13-year-old male and a 36-year-old female were positive at a titer of 1:80 speckled pattern with an anti-ENA against RNP. Both had low positive values for the anti-RNP, 1.1 AI, and 1.7 AI, respectively.
However, a 29-year-old female had an ANA titer of 1:320 homogenous pattern with a low positive (1.1 AI) anti-ENA against Scl-70 alone.
| DISCUSSION
Hepatitis C virus infection is often associated with extrahepatic symptoms such as arthritis, vasculitis and sicca syndrome that might suggest an immune mediated or rheumatic disease. 2 The occurrence of T A B L E 2 Clinical characteristics, HCV antibody levels and specific anti-ENA antibodies in HCV-positive and healthy control patients ANA positivity in HCV-positive patients has been extensively studied The anti-ENA test in our study was the BioPlex "ANA screen" test, a multiplex assay designed to compare in sensitivity and specificity to the ANA screen at a titer of 1:80. Comparison to a 1:80 was used since ANA titers less than or equal to 1:80 may have variable clinical significance. 15 In this respect, the 14% positivity rate in our study compares relatively well to other studies in which the ANA positivity rate for HCV serologically positive patients was 12%-17.9%.
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Additionally, we found anti-ENA positivity to SSB, Scl-70, RNP, anti-dsDNA, Sm, Sm/RNP, and centromere B in our HCV-positive patients. Batchoun et al. 13 83.3% overall agreement of the BioPlex multiplex system with IFA. 16 In our study, the BioPlex multiplex system appeared to be more sen- 
